ATHE
Alterity Therapeutics Limited [ATHE] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ATHE Stock Summary
Top 10 Correlated ETFs
ATHE
Top 10 Correlated Stocks
ATHE
In the News
ATHE Financial details
Company Rating
-
Market Cap
22.96M
Income
-9.81M
Revenue
3.56M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
11
Optionable
No
Shortable
Yes
Earnings
30 Aug 2024
P/E
-892.09
Forward P/E
-
PEG
394.01
P/S
5.06
P/B
207.35
P/C
-
P/FCF
-1.18
Quick Ratio
5.58
Current Ratio
6.17
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0
EPS next Y
-
EPS next Q
-
EPS this Y
7.55%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-78.36%
Revenue last 5Y
-100%
Revenue Q/Q
6.44%
EPS Q/Q
-
-
-
-
-
SMA20
-11.55%
SMA50
19.41%
SMA100
20.12%
Inst Own
-
Inst Trans
-
ROA
-19%
ROE
-24%
ROC
-0.24%
Gross Margin
93%
Oper. Margin
-352%
Profit Margin
-337%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.55-5.41
52W High
-15.8%
52W Low
+321%
RSI
51.69
Rel Volume
0.98
Avg Volume
55.38K
Volume
54.38K
Perf Week
4.99%
Perf Month
-7.27%
Perf Quarter
38.94%
Perf Half Y
25.67%
-
-
-
-
Beta
0.765
-
-
Volatility
0.15%, 0.29%
Prev Close
2.43%
Price
4.21
Change
3.95%
Company Profile
- Volume Average 55.38K
- Market Capitalization 22.96M
- Employee 11
- CEO Dr. David A. Stamler M.D.
- Headquarters Melbourne,VIC,AU
- IPO Date 2003-09-29
-
Website
https://alteritytherapeutics.com 
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
